Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information and the Emergence of a Specific Concern

The legacy of general health and science information has long served as a foundational resource for public understanding of medical conditions and pharmaceutical interventions. Within this broad context, discussions of bone health and the management of osteoporosis have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This established body of knowledge provides a necessary baseline for recognizing how therapeutic exposure can, in certain populations, be associated with adverse outcomes. As the scientific community has refined its focus, a specific concern has emerged regarding the potential link between Fosamax use and the development of osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, represents a shift from general health considerations to a more targeted risk assessment. The transition from a broad informational heritage to a concentrated occupational exposure concern is marked by the need to evaluate how prolonged pharmaceutical exposure—particularly in patients with underlying dental pathology or those undergoing invasive dental procedures—may elevate the risk of this serious complication. This pivot requires a careful examination of exposure duration, dosage, and patient-specific factors, moving beyond general health advice to a nuanced understanding of iatrogenic risk within clinical and occupational settings.

Bridging from General Health to Specific Risk: Fosamax and ONJ

Building on the legacy of general health information, the focus now narrows to the specific risk of osteonecrosis of the jaw (ONJ) associated with Fosamax (alendronate). Fosamax is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, and may be accompanied by local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the condition often occurring spontaneously but more commonly associated with invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors for Fosamax-Associated ONJ

The mechanistic pathways linking Fosamax to ONJ involve several factors. Bisphosphonates, including alendronate, accumulate in bone and inhibit osteoclast activity, which can suppress normal bone remodeling. In the jawbone, which has high turnover rates due to constant mechanical stress from chewing and dental procedures, this suppression may impair healing after minor trauma or infection. The multiscale characterization of jawbone in animal models has provided insights into how bisphosphonate treatment affects jawbone structure, including changes in tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings help understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). The risk of ONJ is increased with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as with concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures are also recognized risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The duration of bisphosphonate exposure may increase the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, they may not fully address the cumulative risk over extended use. Causation-related considerations for affected patients are complex. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with similar symptoms were comparable in the Fosamax and placebo groups, indicating that not all cases are directly attributable to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate, supporting a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, establishing causation requires considering the presence of other risk factors, such as dental procedures, cancer diagnosis, or concomitant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm is variable. Symptoms can appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that patients on long-term therapy are at higher risk, though cases have been reported after short-term exposure. The delayed healing associated with ONJ often becomes apparent after dental procedures, which may occur months or years after starting Fosamax.

Summary of Scientific Evidence and Clinical Implications

In summary, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw, with mechanistic pathways involving suppressed bone remodeling and increased susceptibility to dental trauma or infection. Warnings in the prescribing information address this risk, but the variable onset and multifactorial nature of ONJ complicate individual causation assessments. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis against the potential risk of ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence supports a causal association between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Mechanistic pathways involve suppression of bone remodeling due to osteoclast inhibition, leading to impaired healing after dental trauma or infection. Animal models show changes in jawbone structure and mechanical stability (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical data indicate that ONJ risk increases with invasive dental procedures and longer bisphosphonate exposure, and recurrence upon rechallenge supports causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors for ONJ in Fosamax users include invasive dental procedures (tooth extraction, implants, boney surgery), concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of use, but cases have been reported after short-term exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.